



IFW

PATENT
ATTORNEY DOCKET NO. 01948/088004

Certificate of Mailing: Date of Deposit: February 7, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Santa Zingariello
Printed name of person mailing correspondence

Santa Zingariello
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Karumanchi et al. Art Unit: 1645

Serial No.: 10/624,809 Examiner:

Filed: July 21, 2003 Customer No.: 21559

Title: METHODS OF DIAGNOSING AND TREATING PRE-ECLAMPSIA AND ECLAMPSIA

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the

merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: February 7, 2005


Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 7

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	01948/088004 10/624,809 Karumanchi et al. July 21, 2003 1645 February 7, 2005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,194,596	3/16/1993	Tischer et al.			
	5,219,739	6/15/1993	Tischer et al			
	5,238,819	8/24/1993	Roberts et al.			
	5,240,848	8/31/1993	Keck et al.			
	5,332,671	7/26/1994	Ferrara et al.			
	5,543,138	8/6/1996	Keith			
	5,712,395	1/27/1998	App et al.			
	5,763,441	6/9/1998	App et al.			
	5,830,879	11/3/1998	Isner			
	6,100,071	8/8/2000	Davis-Smyth et al.			
	6,258,787	7/10/2001	Isner			
	6,365,157	4/2/2002	Rockwell et al.			
	6,399,585	6/4/2002	Larson et al.			
	6,410,322	6/25/2002	Robinson			
	6,447,768	9/10/2002	Van Zonneveld et al.			
	6,677,300	1/13/2004	Schreiner et al.			
	2003/0114412	6/19/2003	Ward et al.			
	2003/0220262	11/27/2003	Schreiner et al.			
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 01948/088004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/624,809
		Applicant Karumanchi et al.
		Filing Date July 21, 2003
		Group 1645
		IDS Filed February 7, 2005
(37 C.F.R. § 1.98(b))		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 98/28006	7/2/1998	WIPO			
	WO 02/37120	5/10/2002	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Ahmed et al., "Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) and Soluble Flt-1 by Oxygen--A Review," <i>Placenta</i> 21:S16-S24 (2000).					
	Baek et al., "Hypoxia-Induced VEGF Enhances Tumor Survivability Via Suppression of Serum Deprivation-Induced Apoptosis," <i>Oncogene</i> 19:4621-4631 (2000).					
	Barleon et al., "Soluble VEGFR-1 Secreted by Endothelial Cells and Monocytes is Present in Human Serum and Plasma from Healthy Donors," <i>Angiogenesis</i> 4:143-154 (2001).					
	Baumgartner et al., "Constitutive Expression of phVEGF ₁₆₅ After Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients with Critical Limb Ischemia," <i>Circulation</i> 97:1114-1123 (1998).					
	Belgore et al., "Measurement of Free and Complexed Soluble Vascular Endothelial Growth Factor Receptor, Flt-1, in Fluid Samples: Development and Application of Two New Immunoassays," <i>Clin. Sci.</i> 100:567-575 (2001).					
	Belgore et al., "Plasma Levels of Vascular Endothelial Growth Factor and Its Soluble Receptor (sFlt-1) in Essential Hypertension," <i>Am. J. Cardiol.</i> 87:805-807 (2001).					
	Belgore et al., "sFlt-1, a Potential Antagonist for Exogenous VEGF," <i>Circulation</i> 102:E108-E109 (2000).					
	Belgore et al., "Successful Therapy Reduces Levels of Vascular Endothelial Growth Factor (VEGF) in Patients with Hypertension and Patients with Hypercholesterolemia," <i>Atherosclerosis</i> 151:599 (2000).					
	Belgore et al., "Vascular Endothelial Growth Factor and its Receptor, Flt-1, in Smokers and Non-Smokers," <i>Br. J. Biomed. Sci.</i> 57:207-213 (2000).					
	Blann et al., "Plasma Vascular Endothelial Growth Factor and Its Receptor Flt-1 in Patients with Hyperlipidemia and Atherosclerosis and the Effects of Fluvastatin or Fenofibrate," <i>Am. J. Cardiol.</i> 87:1160-1163 (2001).					
	Bouletreau et al., "Hypoxia and VEGF Up-Regulate BMP-2 mRNA and Protein Expression in Microvascular Endothelial Cells: Implications for Fracture Healing," <i>Plast. Reconstr. Surg.</i> 109:2384-2397 (2002).					
	Celletti et al., "Effect of Human Recombinant Vascular Endothelial Growth Factor165 on Progression of Atherosclerotic Plaque," <i>J. Am. Coll. Cardiol.</i> 37:2126-2130 (2001).					
	Charnock-Jones et al., Determination of the Circulating Levels of the Soluble Form of the VEGF-R1 (sFlt-1) in Women at High Risk of Developing Pre-Eclampsia," <i>J. Soc. Gynecol. Investig.</i> 10:166A Abstract No. 230 (2003).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 01948/088004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/624,809
		Applicant Karumanchi et al.
		Filing Date July 21, 2003
		Group 1645
(37 C.F.R. § 1.98(b))		IDS Filed February 7, 2005

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Charnock-Jones et al., "Identification and Localization of Alternately Spliced mRNAs for Vascular Endothelial Growth Factor in Human Uterus and Estrogen Regulation in Endometrial Carcinoma Cell Lines," <i>Biol. Reprod.</i> 48:1120-1128 (1993).
	Clark et al., "A Vascular Endothelial Growth Factor Antagonist is Produced by the Human Placenta and Released into the Maternal Circulation," <i>Biol. Reprod.</i> 59:1540-1548 (1998).
	Cockell et al., "Human Placental Syncytiotrophoblast Microvillous Membranes Impair Maternal Vascular Endothelial Function," <i>Br. J. Obstet. Gynaecol.</i> 104:235-240 (1997).
	Cohen et al., "Amelioration of Diabetic Nephropathy by Treatment with Monoclonal Antibodies Against Glycated Albumin," <i>Kidney Int.</i> 45:1673-1679 (1994).
	Deodato et al., "Recombinant AAV Vector Encoding Human VEGF165 Enhances Wound Healing," <i>Gene Ther.</i> 9:777-785 (2002).
	Eddahibi et al., "Imbalance Between Platelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Pulmonary Hypertension," <i>Am. J. Respir. Crit. Care Med.</i> 162:1493-1499 (2000).
	Eremina et al., "Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases," <i>J. Clin. Invest.</i> 111:707-716 (2003).
	Ferguson, "Meeting Highlights: Highlights of the 48 th Scientific Sessions of the American College of Cardiology," <i>Circulation</i> 100:570-575 (1999).
	Ferrara et al., "The Role of Vascular Endothelial Growth Factor in Angiogenesis," <i>Acta Haematol.</i> 106:148-156 (2001).
	Freedman et al., "Therapeutic Angiogenesis for Coronary Artery Disease," <i>Ann. Intern. Med.</i> 136:54-71 (2002).
	Gille et al., "Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)," <i>J. Biol. Chem.</i> 276:3222-3230 (2001).
	Graubert et al., "Vascular Repair After Menstruation Involves Regulation of Vascular Endothelial Growth Factor-Receptor Phosphorylation by sFLT-1," <i>Am. J. Pathol.</i> 158:1399-1410 (2001).
	Hayashi et al., "Changes in Urinary Excretion of Six Biochemical Parameters in Normotensive Pregnancy and Preeclampsia," <i>Am. J. Kidney Dis.</i> 39:392-400 (2002).
	He et al., "Alternative Splicing of Vascular Endothelial Growth Factor (VEGF)-R1 (FLT-1) Pre-mRNA is Important for the Regulation of VEGF Activity," <i>Mol. Endocrinol.</i> 13:537-45 (1999).
	He et al., "Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src," <i>J. Biol. Chem.</i> 274:25130-25135 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 01948/088004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/624,809
		Applicant Karumanchi et al.
		Filing Date July 21, 2003
		Group 1645
		IDS Filed February 7, 2005
(37 C.F.R. § 1.98(b))		

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Heeschen et al., "Nicotine Stimulates Angiogenesis and Promotes Tumor Growth and Atherosclerosis," <i>Nat. Med.</i> 7:833-839 (2001).
	Henry, et al., "Intracoronary Administration of Recombinant Human Vascular Endothelial Growth Factor to Patients with Coronary Artery Disease," <i>Am. Heart J.</i> 142:872-880 (2001).
	Holzgreve et al., "Disturbed Feto-Maternal Cell Traffic in Preeclampsia," <i>Obstet. Gynecol.</i> 91:669-672 (1998).
	Hornig et al., "Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids," <i>Lab. Invest.</i> 80:443-454 (2000).
	Isner et al., "VEGF Gene Transfer for Diabetic Neuropathy," <i>Hum. Gene Ther.</i> 12:1593-1594 (2001).
	Isner, "Myocardial Gene Therapy," <i>Nature</i> 415:234-239 (2002).
	Kabbinavar et al., "Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) with FU/LV Alone in Patients with Metastatic Randomized Colorectal Cancer," <i>J. Clin. Oncol.</i> 21:60-65 (2003).
	Kaku et al., "Effects of Vascular Endothelial Growth Factor on Osteoclast Induction During Tooth Movement in Mice," <i>J. Dent. Res.</i> 80:1880-1883 (2001).
	Kendall et al., "Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR," <i>Biochem. Biophys. Res. Commun.</i> 226:324-328 (1996).
	Kendall et al., "Inhibition of Vascular Endothelial Cell Growth Factor Activity by an Endogenously Encoded Soluble Receptor," <i>Proc. Natl. Acad. Sci.</i> 90:10705-10709 (1993).
	Kincaid-Smith, "The Renal Lesion of Preeclampsia Revisited," <i>Am. J. Kidney Dis.</i> 17:144-148 (1991).
	Knebelmann et al., "Transforming Growth Factor α Is a Target for the Von Hippel-Lindau Tumor Suppressor," <i>Cancer Res.</i> 58:226-231 (1998).
	Koga et al., "Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia," <i>J. Clin. Endocrinol. Metab.</i> 88:2348-2351 (2003).
	Koransky, "VEGF Gene Delivery for Treatment of Ischemic Cardiovascular Disease," <i>Trends Cardiovasc. Med.</i> 12:108-114 (2002).
	Kuo et al., "Comparative Evaluation of the Antitumor Activity of Antiangiogenic Proteins Delivered by Gene Transfer," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 98:4605-4610 (2001).
	Lai et al., "Inhibition of Angiogenesis by Adenovirus-Mediated sFlt-1 Expression in a Rat Model of Corneal Neovascularization," <i>Hum. Gene Ther.</i> 12:1299-1310 (2001).
	Lai et al., "Potential Long-Term Inhibition of Ocular Neovascularisation by Recombinant Adeno-Associated Virus-Mediated Secretion Gene Therapy," <i>Gene Ther.</i> 9:804-813 (2002).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 01948/088004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/624,809
		Applicant Karumanchi et al.
		Filing Date July 21, 2003
		Group 1645
(37 C.F.R. § 1.98(b))		IDS Filed February 7, 2005

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Lain et al., "Contemporary Concepts of the Pathogenesis and Management of Preeclampsia," <i>JAMA</i> 287:3183-3186 (2002).
	LeCouter et al., "Identification of an Angiogenic Mitogen Selective for Endocrine Gland Endothelium," <i>Nature</i> 412:877-884 (2001).
	Levine et al., "Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods," <i>Control Clin. Trials</i> 17:442-469 (1996).
	Levine et al., "Trial of Calcium to Prevent Preeclampsia," <i>N. Engl. J. Med.</i> 337:69-76 (1997).
	Lip et al., "Plasma VEGF and Soluble VEGF Receptor FLT-1 in Proliferative Retinopathy: Relationship to Endothelial Dysfunction and Laser Treatment," <i>Invest. Ophthalmol. Vis. Sci.</i> 41:2115-2119 (2000).
	Luttun et al., "Soluble VEGF Receptor Flt1: The Elusive Preeclampsia Factor Discovered?" <i>J. Clin. Invest.</i> 111:600-602 (2003).
	Masuda et al., "Vascular Endothelial Growth Factor Enhances Glomerular Capillary Repair and Accelerates Resolution of Experimentally Induced Glomerulonephritis," <i>Am. J. Pathol.</i> 159:599-608 (2001).
	Maynard et al., "Excess Placental Soluble fms-Like Tyrosine Kinase 1 (sFlt1) May Contribute to Endothelial Dysfunction, Hypertension, and Proteinuria in Preeclampsia," <i>J. Clinical Invest.</i> 111:649-658 (2003).
	Mills et al., "Prostacyclin and Thromboxane Changes Predating Clinical Onset of Preeclampsia," <i>JAMA</i> 281:356-362 (1999).
	Morbidelli et al., "Nitric Oxide Mediates Mitogenic Effect of VEGF on Coronary Venular Endothelium," <i>Am. J. Physiol.</i> 270:H411-H415 (1996).
	Mortensen et al., "Smoking, Sex of the Offspring, and Risk of Placental Abruption, Placenta Previa, and Preeclampsia: A Population-Based Cohort Study," <i>Acta Obstet. Gynecol. Scand.</i> 80:894-898 (2001).
	Myers et al., "Hypertensive Diseases and Eclampsia," <i>Curr. Opin. Obstet. Gynecol.</i> 14:119-125 (2002).
	Neufeld et al., "Similarities and Differences Between the Vascular Endothelial Growth Factor (VEGF) Splice Variants," <i>Cancer Metastasis Rev.</i> 15:153-158 (1996).
	Newman et al., "Cigarette Smoking and Pre-Eclampsia: Their Association and Effects on Clinical Outcomes," <i>J. Matern. Fetal. Med.</i> 10:166-170 (2001).
	Nishimoto et al., "Glomerular Hypertrophy in Preeclamptic Patients with Focal Segmental Glomerulosclerosis: A Morphometric Analysis," <i>Clin. Nephrol.</i> 51:209-219 (1999).
	Ong et al., "First-Trimester Maternal Serum Levels of Placenta Growth Factor as Predictor of Preeclampsia and Fetal Growth Restriction," <i>Obstet. Gynecol.</i> 98:608-611 (2001).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 01948/088004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/624,809
		Applicant Karumanchi et al.
		Filing Date July 21, 2003
		Group 1645
(37 C.F.R. § 1.98(b))		IDS Filed February 7, 2005

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ostendorf et al., "VEGF ₁₆₅ Mediates Glomerular Endothelial Repair," <i>J. Clin. Invest.</i> 104:913-923 (1999).
	Page et al., "Excessive Placental Secretion of Neurokinin B During the Third Trimester Causes Pre-Eclampsia," <i>Nature</i> 405:797-800 (2000).
	Parry et al., "Dinucleotide Repeat Polymorphisms within the Flt-1 Gene in Minimal Change Nephropathy," <i>Eur. J. Immunogenet.</i> 26:321-323 (1999).
	Paternoster et al., "Markers of Tubular Damage in Pre-Eclampsia," <i>Minerva Ginecol.</i> 51:373-377 (1999).
	Polliotti et al., "Second-Trimester Maternal Serum Placental Growth Factor and Vascular Endothelial Growth Factor for Predicting Severe, Early-Onset Preeclampsia," <i>Obstet. Gynecol.</i> 101:1266-1274 (2003).
	Quirici et al., "Differentiation and Expansion of Endothelial Cells from Human Bone Marrow CD 133 ⁺ Cells," <i>Br. J. Haematol.</i> 115:186-194 (2001).
	Regnault et al., "Placental Expression of VEGF, PIGF and their Receptors in a Model of Placental Insufficiency—Intrauterine Growth Restriction (PI-IUGR)," <i>Placenta</i> 23:132-144 (2002).
	Roberts et al., "Pathogenesis and Genetics of Pre-Eclampsia," <i>Lancet</i> 357:53-56 (2001).
	Sato et al., "Increased Pulmonary Vascular Contraction to Serotonin after Cardiopulmonary Bypass: Role of Cyclooxygenase," <i>J. Surg. Res.</i> 90:138-143 (2000).
	Strevens et al., "Glomerular Endotheliosis in Normal Pregnancy and Pre-Eclampsia," <i>Br. J. Obstet. Gynaecol.</i> 110:831-836 (2003).
	Su et al., "Decreased Maternal Serum Placenta Growth Factor in Early Second Trimester and Preeclampsia," <i>Obstet. Gynecol.</i> 97:898-904 (2001).
	Taylor et al., "Longitudinal Serum Concentrations of Placental Growth Factor: Evidence for Abnormal Placental Angiogenesis in Pathologic Pregnancies," <i>Am. J. Obstet. Gynecol.</i> 188:177-182 (2003).
	Tidwell et al., "Low Maternal Serum Levels of Placenta Growth Factor as an Antecedent of Clinical Preeclampsia," <i>Am. J. Obstet. Gynecol.</i> 184:1267-72 (2001).
	Tischer et al., "The Human Gene for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> 266:11947-11954 (1991).
	Tjøa et al., "Plasma Placenta Growth Factor Levels in Midtrimester Pregnancies," <i>Obstet. Gynecol.</i> 98:600-607 (2001).
	Torry et al., "Expression and Function of Placenta Growth Factor: Implications for Abnormal Placentation," <i>J. Soc. Gynecol. Investig.</i> 10:178-88 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 01948/088004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/624,809
		Applicant Karumanchi et al.
		Filing Date July 21, 2003
		Group 1645
		IDS Filed February 7, 2005
(37 C.F.R. § 1.98(b))		

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Torry et al., "Preeclampsia is Associated with Reduced Serum Levels of Placenta Growth Factor," <i>Am. J. Obstet. Gynecol.</i> 179:1539-1544 (1998).
	Traver et al., "Walking the Walk: Migration and other Common Themes in Blood and Vascular Development," <i>Cell</i> 108:731-734 (2002).
	Tsatsaris et al., "Overexpression of the Soluble Vascular Endothelial Growth Factor Receptor in Preeclamptic Patients: Pathophysiological Consequences," <i>J Clin. Endocrinol. Metab.</i> 88:5555-5563 (2003).
	Tucci et al., "rhVEGF and Experimental Rat Skin Flaps: Systemic or Local Administration and Morphological Characteristics," <i>Int. J. Artif. Organs</i> 24:743-751 (2001).
	Vuorela et al., "Amniotic Fluid-Soluble Vascular Endothelial Growth Factor Receptor-1 in Preeclampsia," <i>Obstet. Gynecol.</i> 95:353-357 (2000).
	Walker, "Pre-Eclampsia," <i>Lancet</i> 356:1260-1265 (2000).
	Yang et al., "A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer," <i>N. Engl. J. Med.</i> 349:427-434 (2003).
	Yang et al., "sFlt-1 Gene-Transfected Fibroblasts: A Wound-Specific Gene Therapy Inhibits Local Cancer Recurrence," <i>Cancer Res.</i> 61:7840-7845 (2001).
	Zhang et al., "Birth-Weight-for-Gestational-Age-Patterns by Race, Sex, and Parity in the United States Population," <i>Obstet. Gynecol.</i> 86:200-208 (1995).
	Zhou et al., "Preeclampsia is Associated with Failure of Human Cytotrophoblasts to Mimic a Vascular Adhesion Phenotype. One Cause of Defective Endovascular Invasion in this Syndrome?" <i>J. Clin. Invest.</i> 99:2152-2164 (1997).
	Zhou et al., "Vascular Endothelial Growth Factor Ligands and Receptors that Regulate Human Cytotrophoblast Survival are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome," <i>Am. J. Pathol.</i> 160:1405-1423 (2002).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	